BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, announced today that W. James O’Shea, former President and Chief Operating Officer of Sepracor Inc., has been elected to Ocular’s Board of Directors. “We are very pleased to announce that Jim is joining our Board. With a more than 40-year tenure in the biopharma industry, Jim has ext
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/n7kfbw/global) has announced the addition of the “Global Ophthalmology Devices – Industry Analysis 2015-2019” report to their offering. The global ophthalmology d…
LAS VEGAS–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, announced today that its products will be featured in several presentations and courses at the annual American Academy of Ophthalmology (AAO) meeting being held in Las Vegas, Nevada on November 14 – 17, 2015. In addition, Glaukos will host a major symposium
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that a new international study, published in the November 2015 issue of Clinical Ophthalmology, showed that two iStent® Trabecular Micro-Bypass Stents provided “statistically significant, sustained and safe reduction in intraocular
BOSTON–(BUSINESS WIRE)–Vision Medicines announces exclusive worldwide license from Case Western Reserve University for drug candidate for Stargardt disease. Stargardt leads to legal blindness.
BOSTON–(BUSINESS WIRE)–Vision Medicines announces largest co-funding agreement to date with Foundation Fighting Blindness for Stargardt disease program. Stargardt is an orphan disease that leads to legal blindness.
MARLBOROUGH, Mass.–(BUSINESS WIRE)–Ocata Therapeutics, Inc. (NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™ announced today that it will host a conference call on Monday, November 9th, 2015 at 8:30 a.m. EST, during which it will provide a corporate update for the third quarter of 2015. Interested parties may access the call live by dialing (888) 539-3679 (US) or (719) 325-2370 (international) and using conference ID 1107447. A live audio webcast of the presentation will b
SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today annou…
LEXINGTON, Mass.–(BUSINESS WIRE)–Inotek Pharmaceuticals to Present at the 2015 Ophthalmology Innovation Summit
IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and …
NEW YORK–(BUSINESS WIRE)–Ophthotech Corporation today announced financial results for the third quarter ended September 30, 2015 and provided an update on the Company’s business and product development programs.
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay Pharmaceuticals to report third quarter 2015 financial results and hold an investment community conference call on Friday, November 13, 2015.
BILLERICA, Mass.–(BUSINESS WIRE)–Bruker Corporation (NASDAQ: BRKR) today reported financial results for its third quarter ended September 30, 2015. Bruker’s revenues for the third quarter of 2015 were $396.1 million, a decline of 5.6 percent compared to the third quarter of 2014. Excluding a 2.8 percent negative effect from divestitures, and a 10.9 percent negative effect from changes in foreign exchange rates, Bruker reported year-over-year organic revenue growth of 8.1 percent in the third
SEATTLE–(BUSINESS WIRE)–Acucela Inc. (TOKYO:4589), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, has validated an analytical method that could lead to significant cost savings in the collection of blood samples as part of the company’s clinical trials of emixustat hydrochloride (emixustat), the company announced today. Emixustat, the first inter
RAMSEY, Minn.–(BUSINESS WIRE)–Ophthalmic lens manufacturer VISION EASE immediately expands its product portfolio and distribution capabilities with the acquisition of Daemyung Optical Co. Ltd. (DMO).
SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced that it will present at the 24th Annual Credit Suisse Healthcare Conference on Tuesday, November 10, 2015, at 11:30 a.m. Mountain Standard Time in Scottsdale, Arizona. A live webcast of ACADIA’s presentation will be accessible on the company’
IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), today announced that the Company will host a live webcast in conjunction with its Investor and Media Briefing during the 2015 American Academy of Ophthalmology Meeting on Frida…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Eleven Biotherapeutics Reports Third Quarter 2015 Financial Results. Management to host conference call today at 8:30 a.m. ET
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing and developing non-antibiotic antimicrobial products for the global eye care market, announces plans to report results from a clinical study with its proprietary anti-microbial compound auriclosene (NVC-422) to reduce urinary catheter blockage and encrustation in patients with long-term indwelling urinary catheters in early December. Due to spinal cord inj
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report third quarter 2015 financial results on Tuesday, November 10, 2015. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and webcast at 5:00 p.m. Eastern Time to r